Literature DB >> 30127554

Invasive Fungal Infections in Acute Promyelocytic Leukemia on Dual Differentiating Agents: Real World Data.

Uday Yanamandra1, Parathan Karunakaran2, Alka Khadwal2, Gaurav Prakash2, Deepesh Lad2, Shano Naseem3, Neelam Varma3, Arunaloke Chakrabarti4, Subhash Varma2, Pankaj Malhotra2.   

Abstract

Invasive fungal infection (IFI) in patients with acute promyelocytic leukemia (APL) is a common phenomenon in developing countries. In a systematic study (Dual Inducing Differentiating agents-Indian Trial: DID-IT) using dual differentiating agents (ATO and ATRA) in 98 APL patients at our center we report 18.3% incidence of IFI (n-18). Among all cases of IFI three were definitive, 14 were probable and one was possible IFI. We conclude that incidence of IFI in APL is affected by environmental and therapy related factors and mere usage of dual differentiating agents need not necessarily decrease the incidence of fungal infections.

Entities:  

Keywords:  APL; ATO; ATRA; Fungal infection

Year:  2017        PMID： 30127554      PMCID： PMC6081339          DOI： 10.1007/s12288-017-0894-9

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN： 0971-4502            Impact factor:   0.900


  6 in total

1.  Treatment of therapy related acute promyelocytic leukemia with the combination of all trans retinoic acid and arsenic trioxide without chemotherapy: a series of three patients.

Authors:  Pankaj Malhotra; Neelam Varma; Niraj Arora; Reena Das; Alok Nath; Firuza D Patel; Subhash Varma
Journal:  Leuk Lymphoma       Date:  2010-05

2.  Feasibility and outcome of CT-guided lung biopsy in patients with hematological diseases and suspected fungal pneumonia.

Authors:  Sanjeev Kumar Sharma; Suman Kumar; Avinash Kumar Singh; Tulika Seth; Pravas Mishra; Manoranjan Mahapatra; Sanjay Sharma; Seema Tyagi; Immaculata Xess; Ruma Ray
Journal:  J Infect Dev Ctries       Date:  2013-10-15       Impact factor: 0.968

3.  Risk of invasive fungal infection in patients affected by acute promyelocytic leukaemia. A report by the SEIFEM-D registry.

Authors:  Livio Pagano; Maria Stamouli; Mario Tumbarello; Luisa Verga; Anna Candoni; Chiara Cattaneo; Gianpaolo Nadali; Maria Enza Mitra; Valentina Mancini; Annamaria Nosari; Maria Grazia Garzia; Mario Delia; Sergio Storti; Antonio Spadea; Cecilia Caramatti; Vincenzo Perriello; Marco Sanna; Adriana Vacca; Maria Rosaria De Paolis; Leonardo Potenza; Prassede Salutari; Carlo Castagnola; Rosa Fanci; Anna Chierichini; Lorella Melillo; Marco Picardi; Luca Facchini; Bruno Martino; Roberta Di Blasi; Monica Cesarini; Massimo Offidani; Nicola Vianelli; Morena Caira; Federica Lessi; Antonella Ferrari; Adriano Venditti; Vincenzo Pavone; Francesco Lo-Coco; Franco Aversa; Alessandro Busca
Journal:  Br J Haematol       Date:  2015-01-27       Impact factor: 6.998

4.  Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia.

Authors:  Ardeshir Ghavamzadeh; Kamran Alimoghaddam; Shahrbano Rostami; Seyed Hamidolah Ghaffari; Mohamad Jahani; Massoud Iravani; Seyed Asadollah Mousavi; Babak Bahar; Mahdi Jalili
Journal:  J Clin Oncol       Date:  2011-06-06       Impact factor: 44.544

5.  Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome.

Authors:  M S Tallman; J W Andersen; C A Schiffer; F R Appelbaum; J H Feusner; A Ogden; L Shepherd; J M Rowe; C François; R S Larson; P H Wiernik
Journal:  Blood       Date:  2000-01-01       Impact factor: 22.113

6.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.

Authors:  Ben De Pauw; Thomas J Walsh; J Peter Donnelly; David A Stevens; John E Edwards; Thierry Calandra; Peter G Pappas; Johan Maertens; Olivier Lortholary; Carol A Kauffman; David W Denning; Thomas F Patterson; Georg Maschmeyer; Jacques Bille; William E Dismukes; Raoul Herbrecht; William W Hope; Christopher C Kibbler; Bart Jan Kullberg; Kieren A Marr; Patricia Muñoz; Frank C Odds; John R Perfect; Angela Restrepo; Markus Ruhnke; Brahm H Segal; Jack D Sobel; Tania C Sorrell; Claudio Viscoli; John R Wingard; Theoklis Zaoutis; John E Bennett
Journal:  Clin Infect Dis       Date:  2008-06-15       Impact factor: 9.079
  6 in total
  2 in total

1.  Stem Cell Transplantation in Multiple Myeloma: Very Much Alive and Kicking.

Authors:  Uday Yanamandra; Pankaj Malhotra
Journal:  Indian J Hematol Blood Transfus       Date:  2019-03-13       Impact factor: 0.900

2.  High Risk Acute Promyelocytic Leukemia - An Enigma for Hematologists: Optimizing Treatment with APML-4 Protocol.

Authors:  Jyotsna Kapoor; Sumeet Prakash Mirgh; Narendra Agrawal; Vishvdeep Khushoo; Narender Tejwani; Reema Singh; Pallavi Mehta; Dinesh Bhurani; Rayaz Ahmed
Journal:  Indian J Hematol Blood Transfus       Date:  2021-09-03       Impact factor: 0.900
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.